| Standard Type | Activity Comment |
|---|---|
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Inhibition | = | 20.6 | % |
| Inhibition | = | 14.8 | % |
| Inhibition | = | 43.2 | % |
| Inhibition | = | 34.8 | % |
| Inhibition | = | 82.9 | % |
| Inhibition | = | 32.6 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 5 | % |
| Activity | = | 5 | % |
| Activity | = | 8 | % |
| Activity | = | 5 | % |
| Activity | = | 7 | % |
| Standard Type | Activity Comment |
|---|---|
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 25 | IC50 | = | 25000 | nM | |
| Activity | Not Active | ||||
| 25 | IC50 | = | 25000 | nM | |
| Activity | Not Active | ||||
| Activity | Not Active |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Inhibition | = | 50 | % |
| Inhibition | = | 50 | % |
| Inhibition | = | 60 | % |
| Inhibition | = | 50 | % |
| Inhibition | = | 100 | % |
| Inhibition | = | 50 | % |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 1.032 | Activity | = | 1.032 | uM |
| Standard Type | Standard Relation | Standard Value |
|---|---|---|
| Ratio IC50 | = | 100 |
| Ratio IC50 | = | 100 |
| Ratio IC50 | = | 100 |
| Ratio IC50 | = | 100 |
| Ratio IC50 | = | 100 |
| Ratio IC50 | = | 100 |
| Ratio IC50 | = | 100 |
| Ratio IC50 | = | 100 |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Inhibition | = | 60 | % |
| Inhibition | = | 59 | % |
| Inhibition | = | 60 | % |
| Inhibition | = | 50 | % |
| Inhibition | = | 100 | % |
| Inhibition | = | 100 | % |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|---|
| 0.24 | IC50 | = | 240 | nM | |
| 1000 | IC50 | > | 1000000 | nM | Outside typical range |
| 0.23 | IC50 | = | 230 | nM | |
| 56.37 | IC50 | = | 56370 | nM | |
| 21.76 | IC50 | = | 21760 | nM | |
| 1000 | IC50 | > | 1000000 | nM | Outside typical range |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|---|
| 1.28 | IC50 | = | 1280 | nM | |
| 1000 | IC50 | > | 1000000 | nM | Outside typical range |
| 1.45 | IC50 | = | 1450 | nM | |
| 1000 | IC50 | > | 1000000 | nM | Outside typical range |
| 1000 | IC50 | > | 1000000 | nM | Outside typical range |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|---|
| 6.62 | IC50 | = | 6620 | nM | |
| 1000 | IC50 | > | 1000000 | nM | Outside typical range |
| 2.72 | IC50 | = | 2720 | nM | |
| 1000 | IC50 | > | 1000000 | nM | Outside typical range |
| 1000 | IC50 | > | 1000000 | nM | Outside typical range |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Active |
| Inhibition | % | Active |
| Inhibition | % | Active |
| Inhibition | % | Active |
| Inhibition | % | Active |
| Inhibition | % | Active |
| Inhibition | % | Active |
| Inhibition | % | Active |
| Inhibition | % | Active |
| Inhibition | % | Not Active |
| Inhibition | % | Active |
| Inhibition | % | Not Active |
| Inhibition | % | Active |
| Inhibition | % | Not Active |
| Inhibition | % | Not Active |
| Inhibition | % | Active |
| Inhibition | % | Not Active |
| Inhibition | % | Active |
| Inhibition | % | Not Active |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|---|
| 4800 | IC50 | = | 4800000 | nM | |
| 5000 | IC50 | > | 5000000 | nM | |
| 10000 | IC50 | > | 10000000 | nM | |
| 1300 | IC50 | = | 1300000 | nM | |
| Inhibition | = | 37.6 | % | ||
| 6500 | IC50 | > | 6500000 | nM | |
| 1400 | IC50 | = | 1400000 | nM | Outside typical range |
| 14000 | IC50 | > | 14000000 | nM | Outside typical range |
| Inhibition | = | 16 | % | ||
| 7000 | IC50 | > | 7000000 | nM | |
| Inhibition | = | 20.1 | % | ||
| Inhibition | = | 17.4 | % | ||
| 280 | IC50 | = | 280000 | nM | Outside typical range |
| 7000 | IC50 | > | 7000000 | nM | |
| Inhibition | = | 30 | % | ||
| 390 | IC50 | = | 390000 | nM | Outside typical range |
| 2000 | IC50 | > | 2000000 | nM | Outside typical range |
| 1670 | IC50 | = | 1670000 | nM | |
| 13000 | IC50 | = | 13000000 | nM | Outside typical range |
| 12000 | IC50 | > | 12000000 | nM | Outside typical range |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|---|
| 804 | IC50 | = | 804000 | nM | Outside typical range |
| 24 | IC50 | = | 24000 | nM | |
| 8.5 | IC50 | = | 8500 | nM |
| Standard Type | Activity Comment |
|---|---|
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Standard Type | Activity Comment |
|---|---|
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Standard Type | Activity Comment |
|---|---|
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|---|
| 10 | IC50 | = | 10000 | nM | |
| 141.1 | IC50 | = | 141100 | nM | Outside typical range |
| 29.8 | IC50 | = | 29800 | nM | |
| 65.5 | IC50 | = | 65500 | nM | |
| 65.9 | IC50 | = | 65900 | nM | |
| 60.8 | IC50 | = | 60800 | nM | |
| 110.4 | IC50 | = | 110400 | nM | Outside typical range |
| 8.2 | IC50 | = | 8200 | nM | |
| 30.4 | IC50 | = | 30400 | nM | |
| 10.7 | IC50 | = | 10700 | nM | |
| 40 | IC50 | = | 40000 | nM | |
| 25.5 | IC50 | = | 25500 | nM | |
| 150 | IC50 | > | 150000 | nM | Outside typical range |
| 24 | IC50 | = | 24000 | nM | |
| 57.3 | IC50 | = | 57300 | nM | |
| 39.4 | IC50 | = | 39400 | nM | |
| 73.3 | IC50 | = | 73300 | nM | |
| 150 | IC50 | > | 150000 | nM | Outside typical range |
| 3.2 | IC50 | = | 3200 | nM | |
| 34.3 | IC50 | = | 34300 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 8.9 | IC50 | = | 8900 | nM | |
| Activity | Not Determined | ||||
| Activity | Not Determined | ||||
| Activity | Not Determined | ||||
| Activity | Not Determined | ||||
| Activity | Not Determined | ||||
| 16.1 | IC50 | = | 16100 | nM | |
| 6.5 | IC50 | = | 6500 | nM | |
| Activity | Not Determined | ||||
| 9.6 | IC50 | = | 9600 | nM | |
| 11.3 | IC50 | = | 11300 | nM | |
| 9.9 | IC50 | = | 9900 | nM | |
| Activity | Not Determined | ||||
| Activity | Not Determined | ||||
| 12.9 | IC50 | = | 12900 | nM | |
| Activity | Not Determined | ||||
| Activity | Not Determined | ||||
| Activity | Not Determined | ||||
| 0.4 | IC50 | = | 400 | nM | |
| Activity | Not Determined |
| Standard Type | Activity Comment |
|---|---|
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Standard Type | Activity Comment |
|---|---|
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Standard Type | Activity Comment |
|---|---|
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 39.2 | % |
| Activity | = | 37.4 | % |
| Activity | = | 36.9 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 72.7 | % |
| Activity | = | 85.8 | % |
| Activity | = | 85.2 | % |
| Activity | = | 65.6 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 58.4 | % |
| Activity | = | 69.5 | % |
| Activity | = | 68.7 | % |
| Activity | = | 30.9 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| PPB | = | 45 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| PPB | = | 80 | % |
| PPB | = | 85 | % |
| PPB | = | 85 | % |
| PPB | = | 85 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| PPB | = | 45 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| PPB | = | 80 | % |
| PPB | = | 85 | % |
| PPB | = | 85 | % |
| PPB | = | 85 | % |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Toxic |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Active |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Toxic |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Active |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Active |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Active |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Not Active |
| Species | Strain | IsPseudotypeVirus | AssayMeth | Target | Mutations | IC50Mod | IC50 | IC50Unit | ICOtherPct | ICOtherPctUnit | ICOtherConc | ICOtherConcUnit | KiMod | Ki | KiUnit | Km | KmUnit | HostAnalog | HostAnalogSpecies | RelResFoldChgMod | RelResFoldChg | Comments | Reference | Citation | Other Information |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3' PROCESSING | Integrase | > | 100 | uM | 18662877 | EFFICIENT SYNTHESIS AND UTILIZATION OF PHENYL-SUBSTITUTED HETEROAROMATIC CARBOXYLIC ACIDS AS ARYL DIKETO ACID ISOSTERES IN THE DESIGN OF NOVEL HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2008, 18(16), 4521-4. | |||||||||||||||||||
| 3' PROCESSING | Integrase | > | 100 | uM | 18662877 | EFFICIENT SYNTHESIS AND UTILIZATION OF PHENYL-SUBSTITUTED HETEROAROMATIC CARBOXYLIC ACIDS AS ARYL DIKETO ACID ISOSTERES IN THE DESIGN OF NOVEL HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2008, 18(16), 4521-4. | |||||||||||||||||||
| 3' PROCESSING | Integrase | > | 100 | uM | 18662877 | EFFICIENT SYNTHESIS AND UTILIZATION OF PHENYL-SUBSTITUTED HETEROAROMATIC CARBOXYLIC ACIDS AS ARYL DIKETO ACID ISOSTERES IN THE DESIGN OF NOVEL HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2008, 18(16), 4521-4. | |||||||||||||||||||
| STRAND TRANSFER | Integrase | > | 100 | uM | 18662877 | EFFICIENT SYNTHESIS AND UTILIZATION OF PHENYL-SUBSTITUTED HETEROAROMATIC CARBOXYLIC ACIDS AS ARYL DIKETO ACID ISOSTERES IN THE DESIGN OF NOVEL HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2008, 18(16), 4521-4. | |||||||||||||||||||
| HIV-1 | dTTP incorporation assay by liquid scintillation | Reverse transcriptase | 6.2 | uM | 19442130 | CHARACTERIZATION OF HIV-1 ENZYME REVERSE TRANSCRIPTASE INHIBITION BY THE COMPOUND 6-CHLORO-1,4-DIHYDRO-4-OXO-1-(BETA-D-RIBOFURANOSYL) QUINOLINE-3-CARBOXYLIC ACID THROUGH KINETIC AND IN SILICO STUDIES. Current HIV Research 2009, 7(3), 327-335. | |||||||||||||||||||
| HIV-1 | dTTP incorporation assay by liquid scintillation | Reverse transcriptase | 5.3 | uM | 19442130 | CHARACTERIZATION OF HIV-1 ENZYME REVERSE TRANSCRIPTASE INHIBITION BY THE COMPOUND 6-CHLORO-1,4-DIHYDRO-4-OXO-1-(BETA-D-RIBOFURANOSYL) QUINOLINE-3-CARBOXYLIC ACID THROUGH KINETIC AND IN SILICO STUDIES. Current HIV Research 2009, 7(3), 327-335. | |||||||||||||||||||
| HIV-1 | dTTP incorporation assay by liquid scintillation | Reverse transcriptase | 5 | uM | 19442130 | CHARACTERIZATION OF HIV-1 ENZYME REVERSE TRANSCRIPTASE INHIBITION BY THE COMPOUND 6-CHLORO-1,4-DIHYDRO-4-OXO-1-(BETA-D-RIBOFURANOSYL) QUINOLINE-3-CARBOXYLIC ACID THROUGH KINETIC AND IN SILICO STUDIES. Current HIV Research 2009, 7(3), 327-335. | |||||||||||||||||||
| HIV-1 | N | standard reverse transcriptase assay | Reverse transcriptase | 50 | ug/mL | SYNTHESIS AND HIV-1 REVERSE TRANSCRIPTASE INHIBITION ACTIVITY OF 1,4-NAPHTHOQUINONE DERIVATIVES. Chemistry of Natural Compounds 2012, 47(6), 883-887. | |||||||||||||||||||
| STRAND TRANSFER | Integrase | > | 100 | uM | 18805696 | DISCOVERY OF 3-ACETYL-4-HYDROXY-2-PYRANONE DERIVATIVES AND THEIR DIFLUORIDOBORATE COMPLEXES AS A NOVEL CLASS OF HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry 2008, 16(19), 8988-98. | |||||||||||||||||||
| STRAND TRANSFER | Integrase | > | 100 | uM | 18805696 | DISCOVERY OF 3-ACETYL-4-HYDROXY-2-PYRANONE DERIVATIVES AND THEIR DIFLUORIDOBORATE COMPLEXES AS A NOVEL CLASS OF HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry 2008, 16(19), 8988-98. | |||||||||||||||||||
| 3'-PROCESSING | Integrase | > | 100 | uM | 18805696 | DISCOVERY OF 3-ACETYL-4-HYDROXY-2-PYRANONE DERIVATIVES AND THEIR DIFLUORIDOBORATE COMPLEXES AS A NOVEL CLASS OF HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry 2008, 16(19), 8988-98. | |||||||||||||||||||
| HIV-1 | STRAND TRANSFER | Integrase | 0.015 | uM | 19523819 | N-(4-FLUOROBENZYL)-3-HYDROXY-9;9-DIMETHYL-4-OXO-6;7;8;9-TETRAHYDRO-4H-PYRAZINO[1;2-A]PYRIMIDINE-2-CARBOXAMIDES A NOVEL CLASS OF POTENT HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2009, 19, 4245-9. | |||||||||||||||||||
| HIV-1 | HPLC | Protease | 5.8 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ASSAY | Reverse transcriptase | 170.3 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | HPLC | Protease | 10.2 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ASSAY | Reverse transcriptase | 33.7 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | HPLC | Protease | 24.9 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | 3'-processing | Integrase | > | 100 | uM | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS. . Patent 2009, , . | |||||||||||||||||||
| HIV-1 | Strand Transfer | Integrase | > | 100 | uM | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS. . Patent 2009, , . | |||||||||||||||||||
| HIV-1 | 3'-processing | Integrase | > | 100 | uM | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS. . Patent 2009, , . |
| Species | Strain | IsPseudotypeVirus | AssayMeth | CellType | CellType2 | Target | Mutations | EC50Mod | EC50 | EC50Unit | ECOtherPct | ECOtherPctUnit | ECOtherConc | ECOtherConcUnit | ToxAssayMeth | ToxCellType | CC50Mod | CC50 | CC50Unit | TIMod | TI | RelResFoldChg | Comments | Reference | Citation | Other Information |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIV-1 | LAI | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 1 | uM | 100 | % | 1 | uM | MTT | > | 10 | uM | > | 10 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| HIV-1 | MN | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 0.3 | uM | 76.74 | % | 0.3 | uM | MTT | > | 10 | uM | > | 33.3 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| HIV-1 | MN | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 0.3 | uM | 69 | % | 0.3 | uM | MTT | > | 10 | uM | > | 33.3 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 100 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| R5; CLINICAL ISOLATE | 1(JSL) | P24 | PBMC | Reverse transcriptase | MDR | 0.07 | uM | 90 | % | 1 | uM | MTT | > | 100 | uM | > | 1428 | HIV-1(JSL) WAS ISOLATED FROM PATIENTS WHO RECEIVED ANTIRETROVIRAL THERAPY FOR A LONG PERIOD AND WHOSE VIRUS ACQUIRED A NUMBER OF MUTATIONS IN THE RT- AND PR-ENCODING GENES; DETAILS OF MUTATIONS NOT GIVEN | 15280474 | SPIRODIKETOPIPERAZINE-BASED CCR5 INHIBITOR WHICH PRESERVES CC-CHEMOKINE/CCR5 INTERACTIONS AND EXERTS POTENT ACTIVITY AGAINST R5 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN VITRO. Journal of Virology 2004, 78(16), 8654-8662. | ECOtherConcMod:> | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 3 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:6 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 5 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:7 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 7 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:3 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | LAV | RT | U1(THF-.alpha. STIM) | U1 | Tumor necrosis factor alpha | ~ | 30 | ug/mL | 70 | % | 50 | ug/mL | > | 50 | ug/mL | > | 1.66 | CHRONICALLY HIV-1 INFECTED PROMONOCYTE CELL LINE | 8327469 | THALIDOMIDE INHIBITS THE REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1. Proceedings of the National Academy of Sciences of the United States of America 1993, 90, 5974-5978. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:50 | CCOtherConcUnit:ug/mL | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 75 | % | 10 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 38 | % | 2 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 99 | % | 50 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | ECOtherPctMod:> | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | IIIB | RT | HT4(R116; AZT RESISTANT CELLS) | HT4 | Reverse transcriptase | ~ | 0.01 | uM | 70 | % | 0.01 | uM | ~` | 1 | uM | ~ | 100 | FLOXURIDINE APPEARS TO POTENTIATE AZT ACTIVITY AND ALSO HAVE SOME ANTI-HIV ACTIVITY IN AZT RESISTANT CELL LINES | 8827211 | USE OF FLOXURIDINE TO MODULATE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. AIDS Research and Human Retroviruses 1996, 12(11), 965-968. | ECOtherPctMod:~ | CCOtherPct:35 | CCOtherPctUnit:% | CCOtherConc:.1 | CCOtherConcUnit:uM | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.1 | uM | 52 | % | 0.1 | uM | TRYPAN BLUE | > | 100 | uM | > | 1000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.01 | uM | 78 | % | 0.01 | uM | TRYPAN BLUE | > | 100 | uM | > | 10000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | IIIB | SYNCYT FORM | MOLT-4/H9(HIV-1(IIIB)) | MOLT-4 | gp120 | < | 1 | uM | 95 | % | 10 | uM | -100 | 10 | uM | > | 10 | CHRONICALLY INFECTED H9 CELLS | 9343823 | TRIAZINE DYES INHIBIT HIV-1 ENTRY BY BINDING TO ENVELOPE GLYCOPROTEINS. Microbiology and Immunology 1997, 41(9), 717-724. | CCOtherPct:30 | CCOtherPctUnit:% | CCOtherConc:10 | CCOtherConcUnit:uM | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.01 | uM | 75 | % | 0.01 | uM | TRYPAN BLUE | > | 100 | uM | > | 10000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | 1 | P24 | MT-4 | Integrase | < | 0.25 | uM | 95 | % | 0.25 | uM | MICROSCOPIC EXAMINATION | > | 20 | uM | > | 80 | IN THE PRESENCE OF 50% NHS | 16554152 | A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904. | ECOtherPctMod:> | |||||
| HIV-1 | 1 | P24 | MT-4 | Integrase | < | 0.103 | uM | 95 | % | 0.103 | uM | MICROSCOPIC EXAMINATION | > | 20 | uM | > | 194 | IN THE PRESENCE OF 10% FBS | 16554152 | A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904. | ECOtherPctMod:> | |||||
| HIV-1 | NL4-3 | RT | MT-4 | Reverse transcriptase | < | 1 | uM | 100 | % | 1 | uM | WST-8 | > | 1 | uM | > | 1 | MEASUREMENTS WERE MADE ON DAY 4, 6 AND 8 POST INFECTION | 15371436 | POLYARGININE INHIBITS GP160 PROCESSING BY FURIN AND SUPPRESSES PRODUCTIVE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION. The Journal of Biological Chemistry 2004, 279(47), 49055-49063. | ||||||
| HIV-1 | LAI | RT | HuT 78 | Reverse transcriptase | < | 1 | uM | 57.14 | % | 1 | uM | MTT | > | 10 | uM | > | 10 | MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 42.6 | % |
| Activity | = | 41.3 | % |
| Activity | = | 42.8 | % |
| Activity | = | 45.7 | % |
| Activity | = | 37.2 | % |
| Activity | = | 51.6 | % |
| Activity | = | 59 | % |
| Activity | = | 38.3 | % |
| Activity | = | 40.9 | % |
| Activity | = | 39.6 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 15.7 | % |
| Activity | = | 11.3 | % |
| Activity | = | 11.5 | % |
| Activity | = | 14.8 | % |
| Activity | = | 10 | % |
| Activity | = | 26.8 | % |
| Activity | = | 33.6 | % |
| Activity | = | 10.5 | % |
| Activity | = | 11.8 | % |
| Activity | = | 10.6 | % |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Active |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Toxic |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Activity | > | 80 | % |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Toxic |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Active |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Active |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 95 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Active |